津药药业
(600488)
| 流通市值：56.45亿 | | | 总市值：56.45亿 |
| 流通股本：10.92亿 | | | 总股本：10.92亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,864,212,165.72 | 1,313,057,171.63 | 608,114,103.87 | 2,908,035,191.99 |
| 营业收入 | 1,864,212,165.72 | 1,313,057,171.63 | 608,114,103.87 | 2,908,035,191.99 |
| 二、营业总成本 | 1,754,102,537.8 | 1,194,468,598.58 | 567,269,140.48 | 2,652,987,006.09 |
| 营业成本 | 1,144,078,801.07 | 768,583,666.83 | 352,876,551.76 | 1,718,142,329.47 |
| 税金及附加 | 24,944,172.8 | 14,778,067.5 | 7,025,522.98 | 38,182,116.28 |
| 销售费用 | 200,048,728.35 | 149,250,254.15 | 80,616,197.34 | 356,786,283.71 |
| 管理费用 | 286,234,126.41 | 197,999,015.14 | 96,844,638.1 | 394,840,877.17 |
| 研发费用 | 75,235,583.95 | 47,742,656.96 | 22,321,076.83 | 129,946,501.55 |
| 财务费用 | 23,561,125.22 | 16,114,938 | 7,585,153.47 | 15,088,897.91 |
| 其中:利息费用 | 13,550,087.18 | 9,303,030.36 | 4,844,167.88 | 20,395,065.8 |
| 其中:利息收入 | 3,465,951.05 | 1,935,970.61 | 1,342,577.95 | 9,735,855.94 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 628,765.45 | -86,469.86 | 190,511.44 | -798,682.63 |
| 资产处置收益 | -417,617.12 | -417,617.12 | -417,617.12 | 404,023.42 |
| 资产减值损失(新) | -39,361,917.69 | -60,568,947.97 | -23,398,814.09 | -96,491,611.21 |
| 信用减值损失(新) | -1,190,713.3 | -825,807.21 | -897,683.25 | -47,021.41 |
| 其他收益 | 13,818,899.74 | 10,577,107.83 | 5,589,144.6 | 31,640,333.5 |
| 四、营业利润 | 83,587,045 | 67,266,838.72 | 21,910,504.97 | 189,755,227.57 |
| 加:营业外收入 | 629,438.92 | 454,192.67 | 35,798.52 | 7,043,385.2 |
| 减:营业外支出 | 1,201,220.25 | 393,225.46 | 335,905.62 | 74,688,843.02 |
| 五、利润总额 | 83,015,263.67 | 67,327,805.93 | 21,610,397.87 | 122,109,769.75 |
| 减:所得税费用 | 19,770,873.24 | 15,921,311.72 | 6,355,971.93 | 54,837.53 |
| 六、净利润 | 63,244,390.43 | 51,406,494.21 | 15,254,425.94 | 122,054,932.22 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 63,244,390.43 | 51,406,494.21 | 15,254,425.94 | 122,054,932.22 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 45,699,015.77 | 43,173,512.75 | 13,891,311.04 | 70,564,419.3 |
| 少数股东损益 | 17,545,374.66 | 8,232,981.46 | 1,363,114.9 | 51,490,512.92 |
| 扣除非经常损益后的净利润 | 45,788,134.56 | 42,868,111.73 | 13,967,489.25 | 171,814,599.93 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.04 | 0.04 | 0.01 | 0.07 |
| (二)稀释每股收益 | 0.04 | 0.04 | 0.01 | 0.07 |
| 八、其他综合收益 | 3,462,231.25 | 940,720.35 | -450,224.21 | 17,047,018.45 |
| 归属于母公司股东的其他综合收益 | 3,462,231.25 | 940,720.35 | -450,224.21 | 17,047,018.45 |
| 九、综合收益总额 | 66,706,621.68 | 52,347,214.56 | 14,804,201.73 | 139,101,950.67 |
| 归属于母公司股东的综合收益总额 | 49,161,247.02 | 44,114,233.1 | 13,441,086.83 | 87,611,437.75 |
| 归属于少数股东的综合收益总额 | 17,545,374.66 | 8,232,981.46 | 1,363,114.9 | 51,490,512.92 |
| 公告日期 | 2026-10-24 | 2026-08-26 | 2026-04-25 | 2026-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |